| Literature DB >> 22646664 |
Cindy A Kermott1, Carol S Kuhle, Stephanie S Faubion, Ruth E Johnson, Donald D Hensrud, Mohammad Hassan Murad.
Abstract
BACKGROUND: The benefits of a periodic health evaluation remain debatable. The incremental value added by such evaluations beyond the delivery of age appropriate screening and preventive medicine recommendations is unclear.Entities:
Mesh:
Year: 2012 PMID: 22646664 PMCID: PMC3416642 DOI: 10.1186/1472-6963-12-137
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Baseline demographics of study cohort
| Age, years (± 1 SD) | 50.7 (± 9.5) | 50.7 (± 9.3) | 50.7 (± 9.7) | 1 |
| Concern, n (± 1 SD) | 5.7 (± 3.4) | 5.2 (± 2.9) | 6.2 (± 3.8) | <.001 |
| Diagnoses, n (± 1 SD) | | 9.8 (± 4.0) | 1.6 (± 0.9) | <.001 |
| Gender, n (%) | | | | <.001 |
| Female | 140 (29) | 88 (37) | 52 (21) | |
| Male | 351 (71) | 152 (63) | 199 (79) | |
| Age ranges, n (%) | | | | 0.64 |
| 20-39 | 59 (12) | 32 (13) | 27 (11) | |
| 40-64 | 401 (82) | 194 (81) | 207 (82) | |
| 65+ | 31 (6) | 14 (6) | 17 (7) |
Prevalence of diagnoses
| Adrenal adenoma | 2 (0.4) | 2 | NR |
| Diabetes mellitus Type 2 | 3 (0.6) | 3 | B* |
| Dyslipidemia | 40 (8.2) | 40 | A** |
| Chronic fatigue | 1 (0.2) | 1 | NR |
| Hyperparathyroidism | 6 (1.2) | 6 | NR |
| Hyperthyroidism | 2 (0.4) | 2 | I |
| Elevated lipoprotein (a) | 12 (2.4) | 12 | NR |
| Metabolic syndrome | 6 (1.2) | 6 | NR |
| Obesity | 95 (19.4) | 88 | B |
| Class I | 72 | 67 | |
| Class II | 13 | 12 | |
| Class III | 10 | 9 | |
| Osteoporosis | 9 (1.8) | 8 | B |
| Thyroid nodule | 4 (0.8) | 2 | I |
| Hashimoto’s thyroiditis | 1 (0.2) | 1 | I |
| Thyrotoxicosis | 1 (0.2) | 1 | I |
| Vertebral compression fracture | 2 (0.4) | 2 | NR |
| | |||
| Non-melanoma skin | 8 (1.6) | 8 | I |
| Melanoma | 7 (1.4) | 4 | I |
| Prostate cancer | 4 (0.8) | 4 | D |
| Renal cell carcinoma | 1 (0.2) | 1 | NR |
| Pancreatic cancer | 1 (0.2) | 0 | D |
| | |||
| Colon polyp (large, multiple, tubulovillous+) | 5 (1.0) | 5 | A |
| PSA elevation | 6 (1.2) | 6 | D |
| Night sweats | 2 (0.4) | 0 | NR |
| | |||
| Aortic aneurysm, thoracic | 1 (0.2) | 1 | NR |
| Aortic aneurysm, abdominal | 1 (0.2) | 1 | B |
| Aortic dilatation (any area) | 2 (0.4) | 2 | NR |
| Moderate aortic stenosis | 1 (0.2) | 1 | NR |
| Aortic valve regurgitation | 2 (0.4) | 2 | NR |
| Bicuspid aortic valve | 1 (0.2) | 1 | NR |
| CAD, stable | 3 (0.6) | 3 | D |
| CAD, unstable | 1 (0.2) | 0 | NR |
| Chest pain | 4 (0.8) | 3 | NR |
| LVH | 2 (0.4) | 2 | NR |
| Patent foramen ovale | 1 (0.2) | 1 | NR |
| Abnormal stress test | 2 (0.4) | 2 | D, I*** |
| Congestive heart failure | 1 (0.2) | 0 | NR |
| Peripheral artery disease | 1 (0.2) | 0 | D |
| | |||
| Barrett’s esophagus | 1 (0.2) | 1 | NR |
| Crohn’s disease | 1 (0.2) | 1 | NR |
| Diverticulitis | 4 (0.8) | 3 | NR |
| Diverticulosis | 1 (0.2) | 1 | NR |
| Esophagitis | 6 (1.2) | 5 | NR |
| Helicobacter pylori | 4 (0.8) | 3 | NR |
| Hemochromatosis | 1 (0.2) | 1 | D |
| Hepatitis C | 1 (0.2) | 1 | D |
| Splenomegaly | 2 (0.4) | 2 | NR |
| Steatohepatitis | 8 (1.6) | 8 | NR |
| Mesenteric abscess | 1 (0.2) | 0 | NR |
| Hematochezia | 2 (0.4) | 0 | NR |
| | |||
| Cerebral infarction | 1 (0.2) | 0 | NR |
| Lumbar stenosis | 1 (0.2) | 1 | NR |
| Neuropathy | 6 (1.2) | 2 | NR |
| Paresthesia | 12 (2.4) | 4 | NR |
| Pituitary adenoma | 1 (0.2) | 1 | NR |
| Seizure | 1 (0.2) | 1 | NR |
| Syringomyelia | 1 (0.2) | 1 | NR |
| Spinal syrinx | 1 (0.2) | 1 | NR |
| Gliomatosis cerebri | 1 (0.2) | 0 | NR |
| Transient ischemic attack | 1 (0.2) | 0 | NR |
| | |||
| COPD | 3 (0.6) | 3 | D |
| Obstructive sleep apnea | 24 (4.9) | 11 | NR |
| Pleural effusion | 1 (0.2) | 1 | I |
| Pleural thickening | 1 (0.2) | 1 | I |
| Pneumonitis | 2 (0.4) | 2 | NR |
| Upper airway resistance | 1 (0.2) | 1 | NR |
| Asthma | 1 (0.2) | 0 | NR |
| LTBI | 1 (0.2) | 1 | NR |
| | |||
| IGA nephropathy | 1 (0.2) | 1 | NR |
| Medullary sponge kidney | 1 (0.2) | 1 | NR |
| Nephrolithiasis | 3 (0.6) | 2 | NR |
| Polycystic kidney disease | 2 (0.4) | 2 | NR |
| Prerenal azotemia | 1 (0.2) | 1 | NR |
| Renal insufficiency | 3 (0.6) | 3 | NR |
| | |||
| Macular degeneration | 3 (0.6) | 3 | NR |
| Glaucoma | 4 (0.8) | 4 | I |
| Diabetic retinopathy | 1 (0.2) | 1 | NR |
| | |||
| Depression | 9 (1.8) | 1 | B |
| Eating disorder | 1 (0.2) | 1 | NR |
| Adjustment disorder | 2 (0.4) | 0 | NR |
| Anxiety | 8 (1.6) | 1 | NR |
| | |||
| Alcohol abuse | 5 (1.0) | 1 | B |
| Nicotine dependency | 43 (8.8) | 2 | A |
| | |||
| Hearing loss (severe/asymmetric) | 5 (1.0) | 3 | NR |
| Seronegative spondyloarthropathy | 1 (0.2) | 0 | NR |
| Infertility | 1 (0.2) | 0 | NR |
| Otitis media | 1 (0.2) | 0 | NR |
| | |||
Abbreviations: PSA, prostatic surface antigen; CAD, coronary artery disease; LVH, left ventricular hypertrophy; LTBI, Latent Tuberculosis Infection; COPD, chronic obstructive pulmonary disease; USPSTF, United States Preventive Services Task Force.
Recommendations for average risk patient are considered Grade A- Strongly recommended; Grade B- Recommended; Grade C- No recommendation; Grade d- Recommend against routine use; Grade I- Insufficient evidence to recommend for or against the intervention; NR- No recommendation available.
*Screen in individuals with hypertension, 2 out of 3 individuals met this criteria.
**Screen for men age ±35 and women age ±45.
***D for adults with low risk; I for adults with increased risk for coronary heart disease. ^ elevated PSA did not result in diagnosis of prostate cancer
Logistic regression model to predict presence of at least one new diagnosis
| Male sex | 2.7 | 1.8 | 4.0 | <.0001 |
| No of concerns at presentation | 1.1 | 1.1 | 1.2 | 0.0002 |
| Age | 1.0 | 1.0 | 1.0 | 0.5706 |